JAMA Oncology : Pathologic Complete Response and Clinical Outcomes in Soft Tissue Sarcoma
Interview with Dian Wang, MD, author of Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials. Hosted by Jack West, MD. Related Content: Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - March 30, 2023 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
TWiV 904: 50 years of reverse transcriptase
Vincent travels to Cold Spring Harbor Laboratory to speak with David Baltimore, John Coffin, and Harold Various about the discovery in 1970 of retroviral reverse transcriptase and its impact on life sciences research. Hosts: Vincent Racaniello Guests: David Baltimore, John Coffin, and Harold Varmus Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Fifty Years of Reverse Transcriptase (Cold Spring Harbor Laboratory) 50th Anniversary of RT discovery (Mol Biol Cell) RT in virions of Rous sarcoma virus – Temin (Nature) RNA-dependent DNA polymerase in tumor v...
Source: This Week in Virology - MP3 Edition - May 29, 2022 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Veyondas Future In NSCLC, Sarcomas & Prostate Cancer
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyondas Future In NSCLC, Sarcomas & Prostate Cancer.
Author: Cancer-News
Added: 05/09/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 9, 2019 Category: Cancer & Oncology Source Type: podcasts
George D. Demetri, MD - The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From Established Targets to TRK Inhibition and Beyond (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - January 25, 2019 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
PEMBROSARC: pembrolizumab combinations for advanced sarcoma
Checkpoint inhibitors are an exciting therapy across a range of cancer types. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Maud Toulmonde, MD, of the...
Author: VJOncology
Added: 08/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2018 Category: Cancer & Oncology Source Type: podcasts
Lots of Patients with Refractory Sarcomas Considering Off-Label Checkpoint Inhibitor
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Lots of Patients with Refractory Sarcomas Considering Off-Label Checkpoint Inhibitor
Author: Annual-Meeting
Added: 06/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Undifferentiated Pleomorphic Sarcoma Can respond to checkpoint blockade like pembrolizumab
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Undifferentiated Pleomorphic Sarcoma Can respond to checkpoint blockade like pembrolizumab at ASCO 2018
Author: Annual-Meeting
Added: 06/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Sarcoma Subtypes React to Different Immunotherapy Have inflammatory tumor-immune micro-environments
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Sarcoma Subtypes React to Different Immunotherapy Have inflammatory tumor-immune micro-environments at ASCO 2018
Author: Annual-Meeting
Added: 06/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2018 Category: Cancer & Oncology Source Type: podcasts
FDA Again Advises Against Morcellators for Fibroids
The risk for uterine sarcoma being found in fibroids is too high, notes Dr Markman. (Source: Medscape Oncology)
Source: Medscape Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Response rates to immunotherapy in sarcoma patients and implications for future therapies
Gary K. Schwartz, MD of the Columbia University Medical Center, New York, NY discusses the success and potential of immunology as a treatment for sarcomas. Dr Schwartz explains that sarcoma is a compl...
Author: VJOncology
Added: 08/11/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 11, 2016 Category: Cancer & Oncology Source Type: podcasts
George D. Demetri, MD - New Perspectives on Advanced Soft-Tissue Sarcoma: What Novel Treatment Options Mean for Patient Care
New Perspectives on Advanced Soft-Tissue Sarcoma: What Novel Treatment Options Mean for Patient Care (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - July 25, 2016 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Check-point and T-Cell
SCCA's Dr. Seth Pollack explains why he is excited about immunotherapy in sarcomas, particularly in the next five years.
Author: SeattleCancerCareAlliance
Added: 06/20/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2016 Category: Cancer & Oncology Source Type: podcasts
Treating Sarcoma
Sarcoma expert Seth Pollack, MD discusses the importance of pathology to properly diagnos these rare types of cancer. He also discusses immunotherapy to treat sarcoma.
Author: SeattleCancerCareAlliance
Added: 04/29/2016 (Source: Oncology Tube)
Source: Oncology Tube - April 29, 2016 Category: Cancer & Oncology Source Type: podcasts
TWiV 359: A Blossom by any other name
Host: Vincent Racaniello
Guest: Blossom Damania
Vincent speaks with Blossom about her laboratory's research on Kaposi's sarcoma-associated herpesvirus, including how it transforms cells, the switch between lytic and latent replication, and its interaction with the innate immune system of the host.
Links for this episode
Damania Laboratory
Modulation of cGAS-STING by KSHV (PNAS)
KSHV vIRF1 interacts with ISG15 pathway member (J Virol)
KSHV NLR homolog inhibits inflammasome (Science)
KSHV inhibition of PI3K and mTOR (Blood)
KSHV confers survival advantage to endothelial cells (Cancer Res)
UNC Global Oncolo...
Source: This Week in Virology - MP3 Edition - October 17, 2015 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
